347 Development of optimized CAR T cells for therapy of glioblastoma

作者
Jonathan Khan,Winson Cai,Yanhong Yang,Lauren Dong,Kelsey Hopland,Kenny Kwok Hei Yu,Ruby Freeman,Terence J. Purdon,Viviane S. Tabar,Taha Merghoub,Jedd D. Wolchok,Renier J. Brentjens
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:: A365-A365 被引量:1
标识
DOI:10.1136/jitc-2022-sitc2022.0347
摘要

Background Glioblastoma (GBM) is the most lethal form of primary brain tumor in adults, with a 95% five-year mortality rate. Current therapy consists of surgical resection, chemotherapy, and radiotherapy. However, there remains an urgent need for novel therapies as recent trials have failed to improve overall survival.1 A new approach to target GBM is the administration of Chimeric Antigen Receptor (CAR) T cells to treat relapsed/refractory disease.2 To date, multiple clinical trials employing CAR T cells targeting disparate antigens in the context of GBM have been completed; and analysis of data accrued from these trials identified antigen loss and the upregulation of T cell inhibitory pathways to be major limitations of CAR T cell antitumor efficacy.3,4 Accordingly, we have identified B7-H3 as a potential target antigen for CAR T cell therapy of GBM, and the Programmed Death-1/Programmed Death Ligand-1 (PD-1/PD-L1) axis as an inhibitory pathway suitable for combinatorial immunotherapy with CAR T cell therapy of GBM. Methods B7-H3 expression on U251, U87, and 4 primary GBM cells lines was evaluated by flow cytometry, while patient tumor samples were analyzed by immunofluorescence. B7-H3 targeting CAR T cells were engineered by transducing primary human T cells with a retroviral vector encoding either a CD28-based CAR, or a CD28-based CAR containing a PD-1 blocking scFv. In vitro luciferase-based killing assays, and Luminex-based quantification of cytokine release were used to characterize CAR function. NSG mice were engrafted with U251 GBM cell line and treated with a single peripheral infusion of CAR T cells. Tumors were harvested at various time points following CAR T cell treatment and characterized for T cell infiltrate, T cell phenotype, and expression of checkpoint pathways. Results We demonstrate that B7-H3 is a suitable antigen for CAR T cell therapy of GBM, and that B7-H3-targeting CAR T cells are able to safely, and efficiently control disease progression in a disease-relevant xenograft model. We also show that GBM tumor cells upregulate PD-L1 in direct response to CAR T cell activity, and that CAR T cells upregulate PD-1 following activation through the CAR. We subsequently demonstrate that concomitant PD-1 blockade augments the antitumor capabilities of B7-H3-targeting CAR T cells through increased T cell engraftment and improved effector function to confer durable, long-term remissions in a disease-relevant preclinical model. Conclusions These data demonstrate the concomitant PD-1 blockade is safe and efficient method for improving the antitumor capabilities of B7-H3 targeting CAR T cells in the context of GBM. References Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan, JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol. 2021; 23: iii1–iii105. Bagley SJ, Desai AS, Linette GP, June CH, O’Rourke, DM. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 2018; 20: 1429–1438. Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang W-C, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Porgnow J, D’Apuzzo M, Forman SJ, Jensen MC. Bioactivity and safety of IL13R 2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015; 21: 4062–4072. O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot J-M, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017; 9: eaaa0984. Ethics Approval The human biospecimen analyses were approved by Memorial Sloan Kettering Cancer Center IRB #09-156.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yang发布了新的文献求助10
1秒前
4u发布了新的文献求助10
1秒前
2秒前
orixero的应助被迅速的岩采纳,获得10
3秒前
乌龙茶完成签到 ,获得积分10
3秒前
科研通AI6.3的应助被yaoyinlin采纳,获得10
3秒前
3秒前
3秒前
Owen的应助被七七采纳,获得10
3秒前
5秒前
传奇3的应助被泌尿doctor梁采纳,获得10
5秒前
5秒前
日薪月亿发布了新的文献求助10
6秒前
夙夙发布了新的文献求助10
6秒前
7秒前
7秒前
wifies完成签到,获得积分10
7秒前
Harvest发布了新的文献求助10
7秒前
8秒前
zhao完成签到,获得积分10
8秒前
bkagyin的应助被烊烊采纳,获得10
8秒前
louis发布了新的文献求助10
8秒前
9秒前
9秒前
宋意安完成签到,获得积分10
9秒前
scy完成签到 ,获得积分10
9秒前
4u完成签到,获得积分10
9秒前
晚意发布了新的文献求助10
9秒前
10秒前
10秒前
搜集达人的应助被张张采纳,获得10
10秒前
一月发布了新的文献求助10
10秒前
10秒前
10秒前
酱鱼发布了新的文献求助10
10秒前
11秒前
11秒前
FashionBoy的应助被阿鑫采纳,获得10
11秒前
111发布了新的文献求助10
11秒前
QIU完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178449
求助须知:如何正确求助?哪些是违规求助? 9569267
关于积分的说明 21803160
捐赠科研通 7773332
什么是DOI,文献DOI怎么找? 3432799
关于科研通互助平台的介绍 2556833
邀请新用户注册赠送积分活动 2478436